Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Fenton

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
British Journal of Pharmacology|January 22, 2009
BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headacheK A Maubach, R J Davis, D E Clark, et al.
Journal of Medicinal Chemistry|August 16, 1996
New low-density lipoprotein receptor upregulators acting via a novel mechanismM J Ashton, T J Brown, G Fenton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2B D Curti, D L Longo, A C Ochoa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patientsNaoko Takebe, Xiangfei Cheng, Suhlan Wu, et al.
The New England Journal of Medicine|March 18, 1993
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatinJ W Smith, D L Longo, W G Alvord, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignanciesJ W Smith, W J Urba, B D Curti, et al.
Haematologica|March 1, 2006
Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-pointsAngela Dispenzieri, Morie A Gertz, Martha Q Lacy, et al.
Arthritis Research & Therapy|August 18, 2019
11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapyC G Fenton, C L Doig, S Fareed, et al.
Lupus Science & Medicine|November 15, 2014
Clinical phenotype associations with various types of anti-dsDNA antibodies in patients with recent onset of rheumatic symptoms. Results from a multicentre observational studyMichele Compagno, Ole P Rekvig, Anders A Bengtsson, et al.
International Journal of Molecular Sciences|August 7, 2021
Global Deletion of 11β-HSD1 Prevents Muscle Wasting Associated with Glucocorticoid Therapy in PolyarthritisJustine M Webster, Michael S Sagmeister, Chloe G Fenton, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
British Journal of Pharmacology|January 22, 2009
BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headacheK A Maubach, R J Davis, D E Clark, et al.
Journal of Medicinal Chemistry|August 16, 1996
New low-density lipoprotein receptor upregulators acting via a novel mechanismM J Ashton, T J Brown, G Fenton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2B D Curti, D L Longo, A C Ochoa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patientsNaoko Takebe, Xiangfei Cheng, Suhlan Wu, et al.
The New England Journal of Medicine|March 18, 1993
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatinJ W Smith, D L Longo, W G Alvord, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignanciesJ W Smith, W J Urba, B D Curti, et al.
Haematologica|March 1, 2006
Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-pointsAngela Dispenzieri, Morie A Gertz, Martha Q Lacy, et al.
Arthritis Research & Therapy|August 18, 2019
11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapyC G Fenton, C L Doig, S Fareed, et al.
Lupus Science & Medicine|November 15, 2014
Clinical phenotype associations with various types of anti-dsDNA antibodies in patients with recent onset of rheumatic symptoms. Results from a multicentre observational studyMichele Compagno, Ole P Rekvig, Anders A Bengtsson, et al.
International Journal of Molecular Sciences|August 7, 2021
Global Deletion of 11β-HSD1 Prevents Muscle Wasting Associated with Glucocorticoid Therapy in PolyarthritisJustine M Webster, Michael S Sagmeister, Chloe G Fenton, et al.
Pageof 11